Janus Henderson Group plc amended a Schedule 13G to report beneficial ownership of 1,284,324 shares of Bright Minds Biosciences Inc. (CUSIP 10919W405), representing 13.1% of the class as of 03/31/2026. The filing states the shares are held in multiple managed portfolios for which Janus Henderson is ultimate parent; the Asset Managers exercise shared voting and dispositive power over 1,284,324 shares but disclaim rights to dividends or sale proceeds. The disclosure names Janus Henderson Biotech Innovation Master Fund Ltd. as a managed portfolio holding more than 5% and notes an irrevocable delegation of investment and voting discretion affecting reporting status. The filing is signed by a compliance officer on 5/15/2026.
Positive
None.
Negative
None.
Insights
Large passive stake disclosed through managed portfolios; voting discretion is shared.
Janus Henderson Group plc reports beneficial ownership of 1,284,324 shares or 13.1% of Bright Minds Biosciences as held across Managed Portfolios. The filing attributes shared voting and dispositive power to the Asset Managers rather than sole control.
Key dependencies include the composition of the Managed Portfolios and the cited irrevocable delegation of discretion; subsequent filings may clarify which specific funds hold the shares and any changes to voting arrangements.
Disclosure clarifies reporting boundaries and beneficial ownership via fund structures.
The Schedule 13G/A emphasizes that the Asset Managers exercise investment and voting discretion on behalf of clients, and that dividends/proceeds rights rest with the Managed Portfolios. It also identifies Janus Henderson Biotech Innovation Master Fund Ltd. as holding >5%.
Material follow-ups include any future Section 13 filings if delegation terms or ownership percentages change; the filing's language frames this as allocation and reporting compliance.
Key Figures
Shares beneficially owned:1,284,324 sharesPercent of class:13.1%CUSIP:10919W405+2 more
5 metrics
Shares beneficially owned1,284,324 sharesreported as beneficial ownership on Schedule 13G/A
Percent of class13.1%percent of common stock as stated in filing
CUSIP10919W405Bright Minds Biosciences Common Stock identifier
As of date03/31/2026date tied to the reported ownership amount
Signature date5/15/2026date filing was signed by compliance officer
Key Terms
Beneficial ownership, Managed Portfolios, Irrevocable delegation, Reporting Person
4 terms
Beneficial ownershipregulatory
"may be deemed to be the beneficial owner of 1,284,324 common stock"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Managed Portfoliosfinancial
"collectively referred to herein as Managed Portfolios"
Irrevocable delegationlegal
"Due to an irrevocable delegation of investment and voting discretion"
Reporting Personregulatory
"the Fund is not considered a Reporting Person under Section 13(d) and (g)"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 4)
BRIGHT MINDS BIOSCIENCES INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
10919W405
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
10919W405
1
Names of Reporting Persons
JANUS HENDERSON GROUP PLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
JERSEY
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,284,324.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,284,324.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,284,324.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.1 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
BRIGHT MINDS BIOSCIENCES INC.
(b)
Address of issuer's principal executive offices:
19 VESTRY STREET
NEW YORK, NY 10013
Item 2.
(a)
Name of person filing:
Janus Henderson Group plc
(b)
Address or principal business office or, if none, residence:
201 Bishopsgate
EC2M 3AE, United Kingdom
(c)
Citizenship:
Y9
(d)
Title of class of securities:
Common Stock
(e)
CUSIP No.:
10919W405
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Janus Henderson Group plc (JHG) is the ultimate parent of a number of SEC-registered investment advisers and foreign equivalents thereof, including but not limited to Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, Janus Henderson Investors Australia Institutional Funds Management Limited, Janus Henderson Investors Middle East Limited, Janus Henderson Investors (Jersey) Limited, Janus Henderson Investors (Japan) Limited, Janus Henderson Investors (Singapore) Limited, Kapstream Capital Pty Limited, Privacore Capital Advisors LLC, Tabula Investment Management Limited, and Victory Park Capital Advisors LLC (each, an Asset Manager and together, the Asset Managers). The Asset Managers generally exercise investment and/or voting discretion on behalf of their clients which include investment companies, other investment advisers, institutional separate accounts and retail separate accounts (collectively referred to herein as Managed Portfolios).
As a result of their exercise of investment and/or voting discretion on behalf of the Managed Portfolios, the Asset Managers may be deemed to be the beneficial owner of 1,284,324 common stock of Bright Minds Biosciences, Inc. However, the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights.
(b)
Percent of class:
13.1 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
1284324
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
1284324
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Managed Portfolios have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts.
Of the Managed Portfolios, only the Janus Henderson Biotech Innovation Master Fund Ltd. has the right to receive dividends from, or the proceeds from the sale of, more than five percent of the common stock of Bright Minds Biosciences, Inc. Due to an irrevocable delegation of investment and voting discretion to an Asset Manager on less than 60 days notice, the Fund is not considered a Reporting Person under Section 13(d) and (g).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Please refer to Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
N/A
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
N/A
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What stake does Janus Henderson Group report in Bright Minds Biosciences (DRUG)?
Janus Henderson reports beneficial ownership of 1,284,324 shares, equal to 13.1% of the class as of 03/31/2026. The shares are held across managed portfolios for which Janus Henderson acts as ultimate parent and investment manager.
Does Janus Henderson have sole voting or disposition power over the reported shares?
No. The filing lists 0 shares with sole voting or sole dispositive power and 1,284,324 shares with shared voting and shared dispositive power, indicating collective authority exercised by the Asset Managers on client accounts.
Which fund holds more than 5% of Bright Minds according to the filing?
The Schedule 13G/A identifies Janus Henderson Biotech Innovation Master Fund Ltd. as a Managed Portfolio with the right to receive dividends or proceeds for more than five percent of the common stock of Bright Minds Biosciences.
Why is Janus Henderson not considered a Reporting Person under Section 13(d)/(g)?
The filing explains an irrevocable delegation of investment and voting discretion to an Asset Manager on less than 60 days' notice, which affects reporting status; this contractual delegation is the stated reason for not being a Reporting Person.
